Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein

Robert J. Ragotte,a,b David Pulido,a,b Francesca R. Donnellan,a,b Michelle L. Hill,c Giacomo Gorini,a,b Hannah Davies,a,b Juliane Brun,c Kirsty McHugh,a,b Lloyd D. W. King,a,b Katherine Skinner,a,b Kazutoyo Miura,d Carole A. Long,d Nicole Zitzmann,c Simon J. Draper,a,b

aJenner Institute, University of Oxford, Oxford, United Kingdom
bDepartment of Biochemistry, University of Oxford, Oxford, United Kingdom
cOxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom
dLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

Robert J. Ragotte and David Pulido contributed equally to this work; R.J.R. is listed first as he wrote a larger fraction of the final manuscript.

ABSTRACT Basigin, or CD147, has been reported as a coreceptor used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to invade host cells. Basigin also has a well-established role in Plasmodium falciparum malaria infection of human erythrocytes, where it is bound by one of the parasite’s invasion ligands, reticulocyte binding protein homolog 5 (RHS). Here, we sought to validate the claim that the receptor binding domain (RBD) of SARS-CoV-2 spike glycoprotein can form a complex with basigin, using RHS-basigin as a positive control. Using recombinantly expressed proteins, size exclusion chromatography and surface plasmon resonance, we show that neither RBD nor full-length spike glycoprotein bind to recombinant human basigin (expressed in either Escherichia coli or mammalian cells). Further, polyclonal anti-basigin IgG did not block SARS-CoV-2 infection of Vero E6 cells. Given the immense interest in SARS-CoV-2 therapeutic targets to improve treatment options for those who become seriously ill with coronavirus disease 2019 (COVID-19), we would caution the inclusion of basigin in this list on the basis of its reported direct interaction with SARS-CoV-2 spike glycoprotein.

IMPORTANCE Reducing the mortality and morbidity associated with COVID-19 remains a global health priority. Vaccines have proven highly effective at preventing infection and hospitalization, but efforts must continue to improve treatment options for those who still become seriously ill. Critical to these efforts is the identification of host factors that are essential to viral entry and replication. Basigin, or CD147, was previously identified as a possible therapeutic target based on the observation that it may act as a coreceptor for SARS-CoV-2, binding to the receptor binding domain of the spike protein. Here, we show that there is no direct interaction between the RBD and basigin, casting doubt on its role as a coreceptor and plausibility as a therapeutic target.

KEYWORDS CD147, COVID-19, SARS-CoV-2, basigin, coronavirus, virus entry, virus-host interactions

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the cause of the ongoing coronavirus disease 2019 (COVID-19) pandemic, there has been a rush to identify therapeutic targets that could reduce the immense human and economic toll of COVID-19. While vaccines are highly effective at preventing infection and hospitalization, for individuals who progress to severe disease there are limited, though improving, treatment options (1). Receptors required for viral entry are a natural consideration for druggable targets, as receptor blockade could both...
prevent infection if a drug is delivered prophylactically and treat infection by impeding viral replication to reduce viral load. Moreover, there may be existing monoclonal antibodies (MAbs) approved for clinical use that target these receptors.

After the release of the genome sequence of SARS-CoV-2, the primary entry receptor was rapidly identified as angiotensin-converting enzyme 2 (ACE2) (2–6). This is the same entry receptor used by some other coronaviruses, most notably SARS-CoV, a highly similar coronavirus that emerged in 2002 (2, 7). Since this initial identification of ACE2, there has been significant discussion in the literature, both peer-reviewed and preprint, about other coreceptors or cofactors required for entry (6, 8–10). Transmembrane protease, serine 2 (TMPRSS2), is one such cofactor that has been identified and subsequently validated by multiple groups, which cleaves the spike protein to facilitate entry (6, 11, 12).

CD147, or basigin, was first proffered as a spike glycoprotein coreceptor in preprint literature in March 2020, which has since been published in a peer-reviewed journal (10). The authors showed that spike binding to basigin has important functional implications for viral entry, making basigin blockade an attractive therapeutic target (10). Since this initial finding, basigin has been included in discussions of SARS-CoV-2 coreceptors (8, 13–21).

Basigin is ubiquitously expressed in human tissues and forms a complex with monocarboxylate transporters (MCTs) and the glucose transporter GLUT1, among others (22). In the context of infectious disease, basigin has also been well characterized as an essential receptor for *Plasmodium falciparum* invasion into human erythrocytes, during which it is bound by the malaria parasite’s reticulocyte-binding protein homolog 5 (RH5) (23, 24). Based on the initial observation that appeared to show that basigin binds to the SARS-CoV-2 spike glycoprotein receptor binding domain (RBD) (10), clinical trials were initiated investigating an anti-basigin MAb as a therapeutic for COVID-19 (30) (ClinicalTrials.gov identifier NCT04275245).

Having worked extensively with basigin in the context of its RH5 interaction, we aimed to validate the finding that basigin directly interacts with the receptor binding domain of the SARS-CoV-2 spike protein. Here, we show that we could not replicate this finding. Although we saw clear binding of recombinant SARS-CoV-2 full-length spike trimer (FL-S) and RBD to ACE2 and the anti-RBD MAb CR3022 (26), we did not see any binding to glycosylated or nonglycosylated basigin by size exclusion chromatography (SEC) or surface plasmon resonance (SPR). Meanwhile, recombinant RH5 showed clear binding to both glycosylated and nonglycosylated basigin by the same methods. Finally, we show that anti-basigin polyclonal rabbit IgG can potently inhibit in vitro growth of malaria parasites but has no impact on SARS-CoV-2 infection of Vero E6 cells. In sum, this evidence does not support a role of basigin in SARS-CoV-2 infection.

**RESULTS**

**Spike and RBD bind human ACE2 via SEC.** Initially we produced a panel of recombinant protein reagents. Recombinant human ACE2, SARS-CoV-2 full-length spike trimer (FL-S), full-length nucleoprotein (FL-NP), spike RBD, and anti-RBD antibody CR3022 were all expressed by transient transfection in mammalian Expi293 cells (Fig. 1A and B). Glycosylated and nonglycosylated basigin were expressed in Expi293 cells and *Escherichia coli*, respectively, and glycosylation states were confirmed by PNGase F digest (Fig. S1). Correct folding of RBD and FL-S was confirmed via dot blotting using CR3022, a known SARS-CoV-2 RBD- and FL-S-binding MAb (27), as the primary antibody (Fig. 1C). These data showed that all proteins were expressed as expected and demonstrated high levels of purity. The FL-S and RBD also showed stability upon freeze-thawing and retained binding of the conformation-sensitive MAb CR3022 after three freeze-thaw cycles (Fig. 1C).

We next confirmed SARS-CoV-2 RBD and FL-S binding to human ACE2 using SEC (Fig. 2A). When RBD and ACE2 were incubated together, the complex eluted at an earlier retention volume than ACE2 alone, indicative of the formation of a higher-molecular-weight complex. Complex formation was then confirmed using SDS-PAGE, whereby
CD147 Does Not Directly Interact with SARS-CoV-2 Spike

**FIG 1** (A) Size exclusion chromatograms postpurification of FL-NP, FL-S, CR3022, RBD, and ACE2. All proteins were run individually with chromatograms overlaid. Asterisks indicate the fractions run on SDS-PAGE. (B) Nonreducing (NR) and reducing (R) Coomassie blue-stained SDS-PAGE protein gels of 1 μg of protein from the asterisk-indicated fractions. (C) Freeze-thaw stability of FL-S and RBD. Reducing and nonreducing SDS-PAGE protein gel of 1 μg FL-S (red outline) and RBD (orange outline) after 1, 2, and 3 freeze-thaw cycles. Below each gel a dot blot is shown, using the CR3022 human MAb on 1 μg FL-S and RBD after 1, 2, and 3 freeze-thaw cycles.
both RBD and ACE2 eluted within the same peak at approximately 10 ml, whereas RBD alone normally elutes at approximately 16 ml (Fig. 2A).

This was next confirmed in the same manner with FL-S trimer, which also eluted as a complex with ACE2 when they were incubated together, as shown by SDS-PAGE (Fig. 2B). Although there was only a small change in retention volume between FL-S alone and the FL-S-ACE2 complex, this can be attributed to the use of an S200 column, whose resolution limits are less than the expected size of the FL-S-ACE2 complex (approximately 680 kDa). Nonetheless, it is clear that ACE2 eluted with FL-S at an approximately 8-ml retention volume, while ACE2 alone eluted at approximately 11 ml (Fig. 2B). We next demonstrated there was no interaction between the RH5 malaria antigen and ACE2 (as expected), given that both proteins eluted at the same retention volume.
volume whether alone or mixed together (Fig. 2C). These results confirm that our recombinant FL-S, RBD, and ACE2 demonstrate the established interactions. SARS-CoV-2 spike and RBD do not bind human basigin via SEC. Having confirmed the interaction between FL-S/RBD and ACE2, we proceeded to assess FL-S and RBD binding to glycosylated human basigin using the same method. RH5, which acted as the positive control, showed clear binding to basigin, forming a stable complex in solution, as confirmed by SEC and SDS-PAGE (Fig. 2F). The binding affinity between RH5 and basigin is weaker than the reported values for RBD and basigin (approximately 1 μM for RH5 [23, 24] compared to 185 nM for RBD [10]), indicating that this assay should be sufficiently sensitive to detect the RBD-basigin interaction.

SARS-CoV-2 FL-NP was used as a negative control and did not form a complex with basigin. Coincidentally, both FL-NP and basigin elute at the same retention volume, but the absence of any shift to a higher-molecular-weight complex when they are incubated together is consistent with no complex formation (Fig. 2G). Next, we observed that there was no detectable binding between either RBD or FL-S and glycosylated basigin, with both RBD and FL-S eluting separately from basigin (Fig. 2D and E). Thus, it did not appear that any complex could be formed in solution between these proteins.

Finally, in order to confirm whether glycosylation may affect binding, we performed the experiment again using the basigin ectodomain expressed in E. coli (Fig. S1), as described by Wright et al. (23). Again, there was clear binding to RH5 but no discernible binding to either the FL-S or RBD protein (Fig. S2).

SARS-CoV-2 spike and RBD do not bind to human basigin via SPR. Although it was clear that the reported FL-S/RBD-basigin complex was not stable enough to detect via SEC, we next sought to confirm the previously reported SPR data showing the RBD-basigin interaction (10). To begin, we confirmed that the RBD protein interacted with CR3022 with the expected affinity, via an 8-step dilution curve beginning at 1 μM. The steady-state affinity was determined to be 190 nM, consistent with published data on this interaction (26) (Fig. 3A and B).

Next, basigin, either glycosylated (Fig. 4A to C) or nonglycosylated (Fig. 4D to F), was immobilized through amine conjugation on a CMS chip. RH5, RBD, or FL-NP was then flowed over the chip to determine binding and affinity. RH5 clearly bound to
both forms of basigin with steady-state affinities of approximately $925 \pm 16$ nM for bacterially expressed basigin and $665 \pm 39$ nM for mammalian cell-expressed basigin, in line with previous reports (23, 24) (Fig. 4A and D). However, RBD did not show any discernible binding to either glycosylated (Fig. 4B) or nonglycosylated basigin (Fig. 4E). FL-NP also did not bind to either form of basigin, as expected (Fig. 4C and F).

Anti-basigin polyclonal IgG does not block SARS-CoV-2 infection of Vero E6 cells. In order to rule out the possibility that basigin is indirectly involved in the SARS-CoV-2 invasion process, we measured neutralization of SARS-CoV-2 infection of Vero E6 cells by anti-human basigin polyclonal IgG. We purified polyclonal IgG from rabbits immunized with human basigin and conducted a viral neutralization assay (Fig. 5A). Polyclonal anti-basigin IgG showed no effect on virus neutralization, closely matching the negative-control IgG. As a positive control, we also tested a previously published neutralizing anti-spike MAb, 1B10 (28), which prevented infection in a dose-dependent manner (Fig. 5A).

To ensure that the anti-basigin serum was functional, the same reagent was used to measure inhibition of *P. falciparum* invasion. This clearly demonstrated the functionality of the anti-basigin rabbit IgG, with a 50% effective concentration (EC$_{50}$) of 17 $\mu$g/ml, while the preimmune IgG did not show any neutralizing activity even at 10 mg/ml (Fig. 5B). At 40 $\mu$g/ml, the same top concentration used in the viral neutralization
 assays, 97.3% growth inhibition activity (GIA) was observed (Fig. 5B). These data confirm previously reported results showing that knockdown of basigin did not block viral entry in a CaLu-3 cell viral invasion assay (29), both in contradiction to the original observation that anti-basigin MAbs could neutralize SARS-CoV-2 in vitro (10).

**DISCUSSION**

Here, we show that neither SARS-CoV-2 RBD nor full-length spike trimer binds to recombinant human basigin. Further, anti-basigin polyclonal IgG did not inhibit viral entry. This is in contrast to a previous report which identified basigin as a coreceptor for SARS-CoV-2, showed binding of RBD to spike via SPR assays and ELISA, and showed that meplazumab, an anti-basigin MAb, could neutralize SARS-CoV-2 (10). The use of an anti-basigin MAb in clinical trials has begun on the basis of the original observation that basigin may be required for host cell entry (30). We believe that it is necessary to proceed with caution when interpreting the trial data, as further investigation is warranted to determine what role, if any, basigin has in the SARS-CoV-2 invasion process.

Our findings here are also supported by another independent investigation (29). Shilts et al. also showed evidence that there is no direct interaction between CD147 and full-length spike or its S1 domain using a different set of methods than used here.
Initial evaluation of meplazumab, an anti-basigin antibody, for treatment of SARS-CoV-2 pneumonia suggested that there could be a benefit (30). These results are based on small groups \( (n=17 \text{ in the treatment group}) \) (30); as such, it will be necessary to conduct larger clinical studies to confirm this finding. If indeed these findings hold, the reported effect could be due to a nonspecific anti-inflammatory effect of basigin blockade, as there have been some reports of a proinflammatory role of basigin in immune signaling (32–36). Any benefit of meplazumab is thus unlikely to be due to the direct inhibition of viral entry, due to the fact that SARS-CoV-2 spike protein does not appear to interact with basigin in our study or that of Shilts et al. (29).

Nevertheless, the data surrounding the safety and tolerability of anti-basigin may have implications beyond SARS-CoV-2, as these trials could inform the use of anti-basigin as a malaria prophylactic regardless of its effectiveness in reducing mortality and morbidity due to COVID-19. To date, this has not been pursued in the malaria field beyond in vitro assays (37) or humanized mouse models (38), despite demonstration of remarkable potency of anti-basigin MAbs, further supported here by our GIA assay data using the same polyclonal anti-basigin IgG against *P. falciparum*. This is largely due to safety concerns regarding prophylactics that would target a human host protein, as opposed to the parasite, in a vulnerable or infant target population. Should this therapy prove to be safe and well tolerated, it could be further explored in malaria, where basigin has a well-established role in pathogen invasion.

**Conclusion.** Recombinant basigin (CD147) does not bind directly to the SARS-CoV-2 RBD. The data presented here do not support the role of basigin as a possible SARS-CoV-2 coreceptor.

**MATERIALS AND METHODS**

**Recombinant protein expression and purification.** A construct for soluble trimeric spike (FL-S) glycoprotein of SARS-CoV-2 (NCBI reference sequence YP_009724390.1), encoding residues M1 to P1213 with two sets of mutations that stabilize the protein in a prefusion conformation (removal of a furin cleavage site and the introduction of two proline residues, K986P and V987P), was expressed as described previously (39). This construct includes the endogenous viral signal peptide at the N terminus (residues 1 to 14), while a C-terminal T4-foldon domain is incorporated to promote association of monomers into trimers to reflect the native transmembrane viral protein. The RBD construct utilized the native SARS-CoV-2 spike signal peptide (residues 1 to 14) fused directly to residues R319 to F541 of the spike glycoprotein, which encompasses the binding site for the human receptor ACE2 (39). Both constructs include a C-terminal hexahistidine (His6) tag for nickel-based affinity purification. FL-S and RBD were transiently expressed in Expi293 cells (Thermo Fisher Scientific) and protein purified from culture supernatants by immobilized metal affinity followed by gel filtration in Tris-buffered saline (TBS) (pH 7.4) buffer.

Full-length SARS-CoV-2 nucleoprotein (FL-NP; NCBI reference sequence YP_009724397.2; residues M1 to A419) was transiently expressed in Expi293 cells (Thermo Fisher Scientific) intracellularly. The FL-NP construct included a C-tag peptide (EPEA) at the C terminus (40) for affinity chromatography purification. Using a C-tag affinity resin (Thermo Fisher Scientific), eluting with 20 mM Tris-HCl, 2 M MgCl\(_2\) (pH 7.4). Affinity purification was followed by size exclusion chromatography in TBS (pH 7.4) buffer. Human ACE2 ectodomain (NCBI reference sequence NP_001358344.1; residues Q18 to S740) was expressed in Expi293 cells (Thermo Fisher Scientific) with a preceding murine IgG1 signal peptide, mono-Fc domain, and tobacco etch virus (TEV) cleavage site at the N terminus and a GTGGS flexible linker and C-tag peptide at the C terminus. ACE2-containing supernatant was purified by C-tag affinity followed by size exclusion chromatography in TBS (pH 7.4) buffer. Human IgG1 CR3022 antibody (27) (GenBank accession no. ABA54613.1 and ABA54614.1) was expressed from heavy- and light-chain AbVec expression vectors in Expi293 cells (Thermo Fisher Scientific). CR3022 supernatant was purified using HiTrap protein G HP (Cytiva) followed by size exclusion chromatography in TBS (pH 7.4) buffer. Wild-type/native human basigin (BSG-2; residues M1 to L206) was expressed in Expi293 cells (Thermo Fisher Scientific) with a tag containing C-terminal rat CD4 domains 3 and 4 (CD4d3+4) (to aid expression and solubility), followed by a His6 tag for purification, as described previously (24, 41). Nonglycosylated basigin (also BSG-2) was expressed in *Escherichia coli* with an N-terminal His6 tag followed by a TEV cleavage site, as described previously (23). The recombinant RHS sequence is based on the *P. falciparum* 3D7 clone reference sequence and encodes amino acids E26 to K526. The construct includes a C-terminal C tag and four mutations to delete N-linked glycosylation sequons (T404A, T216A, T286A, and T299A). This construct...
was expressed as a secreted protein by a stable *Drosophila* S2 cell line (42) and affinity purified using C-tag affinity resin (Thermo Fisher Scientific) followed by a size exclusion chromatography polishing step in 20 mM Tris, 150 mM NaCl (pH 7.4).

**SEC binding assay.** One hundred micrograms of recombinant receptor (either mammalian- or *E. coli*-expressed basigin or ACE2) was mixed in a 1:1 molar ratio with R5S, FL-S, or RBD and then incubated for 1 h at room temperature (RT). After incubation, samples were loaded onto a S200 10/300 column via direct injection using an Akta Pure (GE Healthcare) and run at 0.8 ml/min at RT. Eluted fractions were collected and run on SDS-PAGE under reducing or nonreducing conditions before staining with Coomassie blue.

**Protein blots.** Samples were diluted 1:4 in Laemmli buffer, with or without dithiothreitol (DTT), and then heated at 95°C for 5 min before loading onto a precast 4 to 12% bis-Tris polyacrylamide gel (Thermo Fisher Scientific). Samples were run at 200 V for 45 min before staining with Coomassie blue.

**Surface plasmon resonance.** Basigin, expressed in either mammalian cells or *E. coli*, was immobilized on a CM5 chip through amine conjugation using NHS/EDC coupling using a Biacore X100 system (GE Healthcare). Samples were run at 30 µl/min with an injection time of 60 s and a dissociation of 200 s. Then, 5-step 2-fold dilution curves of either R5S, RBD, or FL-NP were run starting at 2 µM, with regeneration of the chip via injection of 10 mM glycine (pH 2) for 30 s. Between runs, a single injection of RH5 at 2 µM was carried out to confirm that there was no loss in binding activity. For CR3022 binding affinity, approximately 400 response units (RU) of antibody was captured on a protein A chip. Steady-state affinity was determined through an 8-step dilution curve beginning at 1 µM, with 10 mM glycine (pH 2) used to regenerate the chip between curves. All curves included one duplicate concentration and were evaluated using the Biacore X100 evaluation software.

**PNGase F treatment.** PNGase F treatment was conducted per the manufacturer's protocol (New England Biolabs). Briefly, 10 µl of basigin at 0.5 µg/µl expressed in either *E. coli* or Exp293 cells underwent denaturation at 95°C for 10 min in glycoprotein denaturing buffer (New England Biolabs) followed by immediate cooling on ice for 10 s. Then, the denatured protein was mixed with 2 µl of GlycoBuffer 2, 2 µl 10% NP-40, 6 µl of water, and 1 µl of PNGase F. After incubation for 1 h at 37°C, samples were analyzed by nonreducing SDS-PAGE and stained with Coomassie blue.

**Anti-basigin polyclonal serum generation.** Work using rabbits was reviewed by the University of Oxford Animal Welfare and Ethical Review Board and conducted by Cambridge Research Biochemicals, UK, in accordance with the terms of the UK Animals (Scientific Procedures) Act Project Licence. A New Zealand White rabbit (Cambridge Research Biochemicals, UK) was immunized with 100 µg recombinant human basigin or *P. falciparum* S antigen (negative control) in 50% (vol/vol) (200 µl total) AddaVax adjuvant (InvivoGen) on days 0, 28, and 56, prior to serum harvest on day 63. Total IgG was purified from serum using protein G columns (Thermo Fisher). Serum was diluted 1:1 in IgG binding buffer (Thermo Fisher) and loaded onto an equilibrated protein G column. The IgG-bound column was then washed with phosphate-buffered saline (PBS), and IgG was eluted with 0.1 M glycine (pH 2) into 1 M Tris HCl (pH 9) to reach a pH of 7.4.

**Virgal neutralization assay.** The SARS-CoV-2 isolate SARS-CoV-2/human/Eng/2-20 was provided as passage 1 from Public Health England and was propagated in Vero E6 cells in Dulbecco's modified Eagle medium (DMEM) with 2% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, and 0.1 mg/ml streptomycin (MilliporeSigma). Antibody neutralization potential was determined using a focus reduction neutralization test (FRNT). Half-log serial dilutions of antibody (purified rabbit IgG) were mixed with SARS-CoV-2 harvested 72 h postinfection (multiplicity of infection = 0.01) and incubated at RT for 30 min before adding to Vero E6 cells and incubating for 2 h at 37°C and 5% CO2, semisolid carboxymethyl cellulose (CMC) (2%; Merck) overlay medium (1:1 mix of 4% CMC in H2O and virus propagation medium) was then added to each well, and plates were incubated for 20 h at 37°C and 5% CO2. After incubation, cell monolayers were fixed with 4% paraformaldehyde and then stained with a monoclonal antibody (against the SARS-CoV-2 spike protein) followed by peroxidase-conjugated secondary antibody (1:1000 dilution). Positive and negative controls were included on each plate. The plates were then incubated with 1000 units of HRP-conjugated LiteBlue substrate (50:78:02; Insight Biotechnologies). Foci were counted using an AID Classic enzyme-linked immunosorbent spot (ELISpot) assay reader (Autoimmun Diagnostika GmbH).

**P. falciparum assay of growth inhibition activity.** Assays of growth inhibition activity (GIA) were done at the GIA Reference Centre, NIAID, NIH, as described previously (43). Briefly, one-cycle GIA was done at the indicated concentration of purified rabbit IgG using tightly synchronized cultures of late trophozoites/schizonts prepared using 5% sorbitol treatment. Invasion of red blood cells was quantified using a *P. falciparum* lactate dehydrogenase assay. Invasion was reported relative to medium alone. All samples were run in triplicate.

**Data availability.** Requests for materials should be addressed to the corresponding author.

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**FIG S1**, TIF file, 1.7 MB.

**FIG S2**, TIF file, 2.7 MB.
REFERENCES

1. Stasi C, Fallani S, Voller F, Silvestri C. 2020. Treatment for COVID-19: an overview. Eur J Pharmacol 889:173644. https://doi.org/10.1016/j.ejphar.2020.173644.

2. Letko M, Marzi A, Munster V. 2020. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 5:562–569. https://doi.org/10.1038/s41556-020-0668-y.

3. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. 2020. Structural basis of receptor recognition by SARS-CoV-2. Nature 581:221–224. https://doi.org/10.1038/s41586-020-2179-y.

4. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. 2020. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367:1444–1448. https://doi.org/10.1126/science.abb2762.

5. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, Wang Q, Zhou H, Yan J, Qi J. 2020. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181:894–904.E9. https://doi.org/10.1016/j.cell.2020.02.052.

6. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, Müller MA, Drosten C, Pöhlmann S. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271–280.EB. https://doi.org/10.1016/j.cell.2020.02.052.

7. Li W, Moore MJ, Yasilova N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzziari K, Greenough TC, Choe H, Farzan M. 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450–454. https://doi.org/10.1038/nature02145.

8. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl JA, Johnstone R, Shin VY, Bortz RH, III, Florez C, Willoughby BA, Walker PA, Kajser S, Riddell A, Moore C, Peli PM, Wilkinson M, Marshall LR, Rossor MC, Radoszewska A, Peckham H, Ciurtin C, Wedderburn LR, Beale R, Swanton C, Gandhi S, Stockinger B, McCauley J, Gamblin SJ, McCoy LE, Cher reparov P, Nastouli E, Kassiotis G. 2020. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 370:1339–1343. https://doi.org/10.1126/science.abb1107.

9. Herrera NC, Morano NC, Celikgil A, Georgiev Gl, Malonis RJ, Lee JH, Tong K, Vargnolle O, Massimi AB, Yen LY, Noble AJ, Kopylov M, Bonannda J, Garrett-Thomson SC, Hayes DB, Bortz RH, III, Wirchanski AS, Florez C, Laudermilch E, Haswander D, Fels JM, Almeida ME, Jangra RK, Bamhill J, Mengotto A, Kimmel D, Daily JP, Pirofski LA, Chandran K, Brenowitz M, Garforth SJ, Eng ET, Lai JR, Almo SC. 2021. Characterization of the SARS-CoV-2 S protein: biophysical, biochemical, structural, and antigenic analysis. ACS Omega 6:85–102. https://doi.org/10.1021/acsof.0c03512.

10. Wang K, Chen W, Zhang Z, Deng Y, Lian J-Q, Du P, Wei D, Zhang Y, Sun X, Gong L, Yang X, He L, Zhang L, Yang Z, Geng J-J, Chen R, Zhang H, Wang B, Zhu Y-M, Nan G, Jiang J-L, Li L, Wu J, Lin P, Huang W, Xie L, Zheng Z-H, Zhang K, Miao J-L, Cui H-Y, Huang M, Zhang J, Fu L, Yang X-M, Zhao Z, Sun S, Gu H, Wang Z, Wang C-F, Li Y, Liu Y-W, Yang Q-Y, Bian H, Zhu P, Chen Z-N. 2020. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther 5:283. https://doi.org/10.1038/s41392-020-00426-x.

11. Matsuyma S, Nao N, Shirato K, Kawase M, Saito S, Takayama Y, Nagata N, Sekizuka T, Katoh H, Kato F, Sakata M, Tahara M, Kutsuna S, Ohmagari N, Kuroda M, Suzuki T, Kayegama T, Takeda M. 2020. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A 117:7001–7003. https://doi.org/10.1073/pnas.2002589117.

12. Zang R, Castro MFG, McCune BT, Zeng Q, Rothlauf PW, Sonnek NM, Liu Z, Bruloiu KS, Wang X, Greenberg HB, Diamond MS, Ciocra MA, Whelan SPJ, Ding S. 2020. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol 5:eabc3582. https://doi.org/10.1126/scienceimmunol.Abc3582.

13. Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, Wang M, Li S, Morita H, Altunbulakli C, Reiger M, Neumann AU, Lunjani C, Traidl-Hoffmann C, Nadeau K, O‘Mahony L, Akdis CA, Sokolovska M. 2020. Distribution of ACE2, CD147, CD26 and other SARS-CoV-2-associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy 75:2829–2845. https://doi.org/10.1111/all.14429.

14. Ulrich H, Pillat MM. 2020. CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement. Stem Cell Rev Rep 16:434–440. https://doi.org/10.1007/s12015-020-09976-7.

15. Zhou H, Fang Y, Xu T, Ni W-J, Shen A-Z, Meng X-M. 2020. Potential therapeutics targets and promising drugs for combating SARS-CoV-2. Br J Pharmacol 177:3147–3161. https://doi.org/10.1111/bph.15092.

16. Illici Sagkan R, Akin-Bali DF. 2020. Structural variations and expression levels of the SARS-CoV-2 host invasion genes in lung cancer. J Med Virol. https://doi.org/10.1002/jmv.26107.
